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Mantle cell lymphoma (MCL) is a rare, aggressive B-cell lymphoma. Ibrutinib (first-in-class, 
once-daily, oral, covalent inhibitor of Bruton’s tyrosine kinase) is highly active in MCL. We 
pooled data from three ibrutinib studies to explore impact of baseline patient characteristics on 
response. Patients with relapsed/refractory MCL received once-daily ibrutinib 560 mg until 
progressive disease/unacceptable toxicity. ORR (n = 370) was 66% (20% CR; 46% PR); 
median DOR, PFS, and OS were 18.6, 12.8 and 25.0 months, respectively. In CR patients, 79% 
were progression-free and 92% were alive at 2 years. Univariate analyses showed patients with 
one versus >one prior line of therapy had significantly longer OS. Multivariate analyses 
identified one prior line of therapy as affecting PFS and ECOG, and sMIPI, bulky disease, 
blastoid histology as affecting OS and PFS. Patients with blastoid versus non-blastoid histology 
had similar time to best response (2.2 vs. 2.1 months), but lower ORR (50.0% vs. 67.8%), DOR 
(8.6 vs. 18.8 months), PFS (5.1 vs. 14.6 months). OS (12.8 vs. not reached at 24 months) was 
significantly shorter in blastoid patients. PFS was significantly improved in patients with one 
versus >one prior line of therapy. OS and PFS were significantly longer in patients with better 
sMIPI scores, patients in ECOG performance status 0–1, non-bulky disease, and non-blastoid 
histology. Multivariate analyses indicated poor prognostic factors adversely impact OS. 
Additionally, proportions of patients with poor prognostic factors increases with increasing lines 
of therapy. Together, results suggest patient outcomes following treatment failure with ibrutinib 
are related to natural biologic evolution of the disease. 
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Mantle cell lymphoma (MCL) is a rare, clinically aggressive B-cell lymphoma that accounts for 
6–8% of all non-Hodgkin lymphoma (Dreyling et al, 2014). It is a disease that predominantly 
affects older men (median age of 65 years), usually presents as late-stage disease and is 
associated with a poor prognosis (Dreyling et al, 2016). The median overall survival (OS) of 
patients with MCL is 4–5 years (Herrmann et al, 2009; Smith et al, 2015). The majority of 
patients respond to initial therapy but then relapse. Following progression, subsequent 
treatment is often ineffective and survival is short (Herrmann et al, 2009). 
 
 Ibrutinib is a first-in-class, once-daily, oral, covalent inhibitor of Bruton’s tyrosine kinase 
(BTK). BTK is a member of the cytoplasmic tyrosine (Tec) kinase family and is important for 
signaling via B-cell receptors and other B-cell surface receptors (Khan, 2012). Ibrutinib binds in 
a potent and covalent manner to a cysteine residue (Cys-481) in the active site ATP-binding 
domain of BTK. This binding inhibits B-cell receptor signalling within the malignant B-cell, 
leading to downstream mitigation of cell growth, proliferation, survival, adhesion, and migration 
(Buggy & Elias, 2012; Cinar et al, 2013; de Rooij et al, 2012; Herman et al, 2011; Honigberg et 
al, 2010; Ponader et al, 2012; Cheng et al, 2014). Based on the results of a phase II study 
(PCYC-1104) in patients with relapsed or refractory (R/R) MCL, ibrutinib was approved in the 
United States, the European Union, and elsewhere around the world for patients with MCL who 
have received at least one prior line of therapy (Wang et al, 2013). 
 
 Two additional studies have been reported with ibrutinib in patients with R/R MCL: the 
phase II MCL2001 (SPARK) (Wang et al, 2014) and phase III MCL3001 (RAY) (Dreyling et al, 
2016) studies. In both of these studies, a high overall response rate (ORR) was seen, which 
appeared to be largely independent of traditional poor-risk prognostic factors associated with 
this disease. Recent reports (Cheah et al, 2015; Martin et al, 2016) suggest that outcomes 





following ibrutinib progression may be poor, but the key question that remains is whether this is 
due to a biologic effect of ibrutinib or to the disease biology of the patient population itself. 
Interestingly, other studies (Dreyling et al, 2016; Rule et al, 2015) suggest that post-progression 
outcomes in ibrutinib-treated patients are less negatively affected, with significantly longer 
progression-free survival 2 (PFS2) with ibrutinib versus temsirolimus. This indicates that 
improvement with ibrutinib is preserved following post-progression treatments. Another major 
finding of this study is that within the ibrutinib-treated cohort, PFS is longer in patients treated 
with one versus more than one prior line of therapy (Fig S1) (Rule et al, 2015). 
 
 In this analysis, we pooled patient-level data from three single-agent ibrutinib studies, 
PCYC-1104, SPARK and RAY (ibrutinib-treated cohort), to further characterize the efficacy 
profile of single-agent ibrutinib in MCL and to assess the best potential place for its use in 
patients with R/R MCL. In particular, an improved understanding of the baseline factors 




Patients with R/R MCL enrolled in three separate studies, PCYC-1104, SPARK and RAY 
(ibrutinib arm only), and received ibrutinib 560 mg orally once daily until progressive disease or 
unacceptable toxicity. Inclusion and exclusion criteria were similar in all three studies; however, 
SPARK required patients to have received prior rituximab and bortezomib, and RAY required 
patients to have received prior rituximab. For further details on eligibility criteria, please refer to 
the individual studies (PCYC-1104 (Wang et al, 2013); SPARK (Wang et al, 2014); RAY 
(Dreyling et al, 2016)). Blastoid histology was not centrally reviewed but was investigator-
categorized at baseline. All patients provided written informed consent. Patient-level data from 
these studies were integrated for analyses. In addition to descriptive statistics for both efficacy 





and safety parameters, exploratory analyses were conducted using Kaplan-Meier estimates for 
efficacy endpoints PFS and OS. Hazard ratios (HR) and 95% confidence intervals (CIs) were 
calculated using both univariate and multivariate Cox regression model. Common prognostic 
factors that were deemed to have prognostic value (P < 0.1) in the univariate analysis and were 
collected in all three studies were included as covariates in a multivariate Cox model adjusted 
by study. The multivariate Cox regression adjusted by study included the following covariates: 
age, extra nodal disease, Eastern Cooperative Oncology Group (ECOG) performance status, 
simplified MCL international prognostic index (sMIPI) risk, prior lines of therapy, bulky disease, 
blastoid histology and bone marrow involvement. ORR was presented over time and by prior 
lines of therapy. Best overall response was summarized by patient baseline characteristics. 
Common treatment-emergent adverse events (AEs) (≥10% of patients) were summarized by 
preferred terms and toxicity grades. 
 
Results 
The baseline demographic and disease characteristics of the individual ibrutinib-treated 
populations (PCYC-1104, n = 111; SPARK, n = 120; RAY, n = 139) were generally comparable, 
although the PCYC-1104 population had a slightly higher proportion of patients with 
intermediate/high-risk MCL (86% vs. 76% in SPARK and 69% in RAY). Full baseline 
characteristics for patients in each trial and for the pooled population (n = 370) are shown in 
Table SI. 
 
 Trial outcomes were similar between PCYC-1104, SPARK, and RAY, respectively: ORR 
was 68%, 63% and 72%; median PFS was 13.9, 10.5 and 14.6 months; median OS was 22.5 
months, 25.4 months and not reached; and estimated OS at 18 months was 58%, 61% and 
58%. Median duration of follow-up for PCYC-1104, SPARK and RAY was 15.5, 14.9 and 20 
months, respectively. 





 For the pooled population, the median age was 67.5 years, with patients having received a 
median of two prior lines of therapy. Seventy-six percent of patients had intermediate/high-risk 
sMIPI and 49% had bulky disease (longest diameter ≥5 cm). The overall median treatment 
duration across the three studies was 11 months, with a median dose intensity of 98.4%, and 
the median duration of follow-up was 24–25 months. Thirty-five percent of patients were still on 
therapy at 18 months. The median PFS of the overall MCL population was 12.8 months and 
median OS was 25.0 months (Fig 1). The median (range) time to first response and best 
response were 2.07 (0 53–13 73) and 2.14 (0.53–24.74) months, respectively. 
 
 Overall, the most common sites of progression were the lymph nodes, with the mediastinum, 
external iliac, and abdominal sites most commonly involved (37%, 35% and 32% of progressed 
patients, respectively). Extranodal sites that were commonly involved at progression were the 
liver, lung, and gastrointestinal tract (34%, 23% and 20% of progressed patients, respectively). 
In total, four (3.1%) patients showed central nervous system (CNS) involvement at progression 
in this poor risk patient cohort (e.g., high sMIPI, 32% of patients, high lactate dehydrogenase 
[LDH] 54% of patients). 
 
 PFS and OS were markedly different in patients based on the number of previous lines of 
therapy. Patients who had received only one prior line of therapy had the longest PFS and OS 
(median not reached), and 2-year PFS and OS estimates were 57% and 68%, respectively (Fig 
2). 
 
 ORRs and complete response (CR) rates improved over time (Fig S2A). Overall, almost one-
third of responders achieved a CR, with an overall CR rate of 20% and partial response (PR) 
rate of 46%. Response rates also differed based on the numbers of prior lines of treatment (Fig 
S2B), non-refractory status, and low sMIPI risk scores. For prior lines of treatment, patients 





treated with ibrutinib at second line achieved the highest ORR and CR rate (73% and 27%, 
respectively) (Fig S2B). The depth of response markedly affected long-term outcomes; patients 
who achieved a CR exhibited the longest PFS and OS (Fig 3): median PFS and OS were not 
reached and with landmark rates of PFS and OS at 2 years of 79% and 92%, respectively. 
 
 ORR (Table SII) was summarized by baseline characteristics. PFS and OS were explored in 
a univariate non-stratified Cox regression model by fitting baseline prognostic factors (Fig 4 and 
Fig S3). PFS and OS outcomes demonstrated similar trends regarding patient outcomes by 
baseline characteristics. Prior bortezomib did not appear to have any effect on PFS or OS. 
Trends toward a difference in outcomes were observed with regard to refractory status, disease 
stage and prior transplant; however, these did not reach statistical significance. Baseline 
characteristics such as age, ECOG performance status, sMIPI risk, prior lines of therapy, bulky 
disease, bone marrow involvement, beta-2 microglobulin (B2M) levels, normal LDH and blastoid 
histology did show statistical significance (Fig 4 and Fig S3). 
 
 Better outcomes were associated with younger age, ECOG performance status 0–1, lower 
sMIPI score, fewer prior lines of therapy, normal LDH levels, lower B2M and non-bulky disease 
or non-blastoid histology (Fig 5 and Fig S4). Patients with blastoid and non-blastoid histology 
had an ORR of 50 0% and 67 8% and time to best response of 2.2 and 2.1 months, 
respectively; however, duration of response (DOR) (8.5 vs. 18.8 months), PFS (5.1 vs. 14.6 
months), and OS (12.8 vs. not reached at 24 months) were significantly shorter in patients with 
blastoid histology. 
 
 Additional exploratory analyses of PFS and OS were performed using a selected set of 
prognostic variables in a multivariate, Cox regression model adjusted by study. The model 
revealed that ECOG performance status, sMIPI, bulky disease and blastoid histology 





significantly affect both PFS and OS, suggesting that each of these factors independently drives 
outcomes. As the multivariate analysis was only significant for PFS for one versus more than 
one prior line of therapy, these results suggest that ibrutinib, independent of baseline factors, 
significantly improves PFS in those patients who receive ibrutinib earlier versus later (Table I). 
 
 Treatment-emergent AEs were reported in 364 (98.4%) patients in the MCL pooled 
population. Grade ≥3 AEs were reported in 265 (71.6%) patients. The most frequently reported 
AEs (any grade) were diarrhoea (n = 146, 39.5%), fatigue (n = 129, 34.9%), cough (n = 81, 
21.9%), nausea (n = 80, 21.6%), peripheral oedema and thrombocytopenia (both n = 74, 
20.0%) (Table SIII). Other AEs of clinical interest occurred in a minority of patients, including 
grade ≥3 atrial fibrillation in 17 (4.6%) patients, and grade ≥3 major bleeding in 18 (4.9%) 
patients. Rash occurred in 57 (15.4%) patients. The incidence of other malignancies was 5.7% 
in the overall population, the majority of which (67%) were non-melanoma skin cancers. 
 
Discussion 
Outcomes are poor for patients with MCL who relapse after initial therapy. Until recently, limited 
treatment options have been available. New targeted therapies in the last decade have been 
added to our armamentarium (e.g., bortezomib, lenalidomide and temsirolimus). These agents 
have activity, but the majority of patients do not respond well and responses are often short-
lived. Ibrutinib was licensed by the US Food and Drug Administration in February 2013, based 
on phase II data in a single-arm study (PCYC-1104) (Wang et al, 2013). The results observed 
with ibrutinib showed ORR and CR rates higher than what had previously been seen with any 
other single agent (Fisher et al, 2006; Hess et al, 2009; Trneny et al, 2016). These results were 
confirmed in two subsequent studies (Dreyling et al, 2016; Wang et al, 2014). The phase III 
RAY study randomized patients to ibrutinib or temsirolimus and demonstrated a significant 
improvement in both ORR and PFS in favour of ibrutinib. 





 The pooled analysis confirms that response rates are consistently high across all the different 
subgroups examined, but PFS and OS are dependent on baseline characteristics. Both 
univariate and multivariate Cox regression models show similar and consistent results; together, 
these analyses indicate that blastoid histology, sMIPI, bulky disease and ECOG performance 
status remain prognostic in terms of PFS and OS with ibrutinib. 
 
 The pooled analysis allows us to look specifically at patients with blastoid histology (n = 44). 
The ORR was 50% in patients with blastoid histology (n = 44); however, both PFS and OS were 
shorter than in patients with non-blastoid histology. This is consistent with outcomes observed 
with other treatments in blastoid MCL (Bhatt et al, 2016). In the pooled analysis, 50% of patients 
with blastoid histology achieved an objective response and best response within 2 to 3 months, 
with a median DOR of 8 months, suggesting that consolidation of a response with bone marrow 
transplant should optimally be performed within 5 to 6 months of starting ibrutinib therapy. 
 
 Results from exploratory analyses of ibrutinib in chronic lymphocytic lymphoma suggest that 
PFS and OS outcomes may improve when ibrutinib is used earlier in treatment (Brown et al, 
2014; Burger et al, 2015). A similar exploratory analysis was conducted in the ibrutinib phase III 
MCL study (Rule et al, 2015), which suggested the same improvement in outcomes (Fig S1). 
The pooled analysis confirms this finding with patients shown to have significantly longer PFS 
and OS when ibrutinib was used after initial relapse versus later in treatment. These results 
were further validated in the multivariate analysis when identifying line of therapy as an 
independent factor for PFS. 
 
In the phase III RAY study, analysis of PFS2 (defined as time to progressive disease after next 
line of therapy, death or start of second subsequent therapy) (Dreyling et al, 2016) show that 
post-progression outcome is poor, independent of prior ibrutinib exposure. In combination with 





those findings, the current results indicate that disease characteristics and line of therapy 
independently impact outcomes with ibrutinib. These findings suggest that the dismal outcomes 
reported after ibrutinib treatment (Cheah et al, 2015; Martin et al, 2016) are attributable mostly 
to adverse disease characteristics. This is further supported by the analysis showing that the 
proportion of patients with poor prognostic factors increases with increasing lines of therapy (Fig 
S5). 
 
 One important finding from this analysis is that the DOR observed with ibrutinib is 
proportionate to the depth of that response. In patients who achieved a CR with ibrutinib, 70% 
were progression-free and 90% were alive at 2 years. These data would support the concept of 
combination regimens involving ibrutinib in an attempt to maximize the CR rate. In R/R MCL, 
Maddocks et al. (Maddocks et al, 2015) previously reported a 94% ORR and 76% CR rate with 
ibrutinib in combination with bendamustine/ rituximab. Prior studies on bendamustine/ rituximab 
(without ibrutinib) demonstrated an ORR/CR of 97%/31% (Flinn et al, 2014) and 82%/40% 
(Czuczman et al, 2015). Wang et al. (Wang et al, 2016) reported an 88% ORR and 44% CR 
rate with ibrutinib plus rituximab. It is unknown whether the PFS and OS rates of the patients 
who achieved CR are similar to those observed in the current pooled analysis. However, this will 
likely be further addressed in the upcoming SHINE phase III study (NCT01776840), in which 
ibrutinib or placebo are being combined with bendamustine and rituximab in treatment-naïve 
patients aged ≥65 years who are not eligible for transplant. 
 
 Clinical reports have recently shown that ibrutinib can penetrate into the CNS, with clinical 
responses reported in patients with Bing-Neel syndrome (Cabannes-Hamy et al, 2016) and 
CNS responses reported in MCL patients (Bernard et al, 2015; Choquet et al, 2016; Grommes 
et al, 2016). Most patients in this pooled analysis had at least one risk factor for CNS 
involvement. In these patients, blastoid histology, the presence of B-symptoms, increased 





serum LDH, ECOG performance status ≥2, and a high sMIPI score are considered risk factors 
for CNS involvement during the course of the disease (Cheah et al, 2013); however, among 
patients who progressed in our pooled analysis, 3.1% showed involvement of the CNS. The role 
of ibrutinib in the treatment of patients with CNS lymphoma is being further explored in clinical 
studies. 
 
 While not the primary focus of this pooled analysis, it is important to comment that in MCL 
and other B-cell malignancies, the overall safety of ibrutinib indicates a favourable risk-benefit 
profile. No new safety signals were observed in any of these three studies, and all of the 
findings were consistent with the known safety profile of ibrutinib in clinical settings. 
 
 These results support the use of ibrutinib earlier in the treatment algorithm, with significant 
improvements in both PFS and OS when used at first relapse rather than later. It also seems 
that the poor prognostic factors that increase in later lines of therapy not only impact traditional 
chemotherapy but also ibrutinib outcomes. However, ibrutinib also appears to overcome some 
of the common poor risk factors such as refractory status and disease stage, and may even 
provide an important option for patients with blastoid histology, allowing them to bridge to 
therapies that may lead to better long-term outcomes. Overall, ibrutinib represents a significant 
advance in the treatment of this challenging lymphoma and further on-going studies will help 
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Table I. Multivariate analysis of progression-free survival (PFS) and overall survival (OS). 
 PFS 
HR (95% CI) 
P value OS 
HR (95% CI) 
P value 
Age <65 years 0.988 (0.722–1.352) 0.9397 0.790 (0.549–1.137) 0.2041 
No extranodal 
disease 0.804 (0.604–1.070) 
0.1340 0.872 (0.633–1.201) 0.4013 
ECOG performance 
status 0–1 0.584 (0.359–0.949) 
 
0.0299* 0.454 (0.263–0.782) 
 
0.0045* 
MIPI     
High risk 2.266 (1.431–3.589) 0.0005* 2.372 (1.401–4.016) 0.0013* 
Intermediate risk 1.624 (1.081–2.440) 0.0195* 1.678 (1.046–2.692) 0.0319* 
One prior line of 
therapy 0.651 (0.448–0.946) 
0.0245* 0.695 (0.459–1.055) 0.0873 
Non-bulky disease 
(<5 cm) 0.703 (0.528–0.938) 
0.0164* 0.608 (0.438–0.844) 0.0029* 
Non-blastoid 
histology 0.442 (0.303–0.646) 
<0.0001* 0.397 (0.259–0.608) <0.0001* 





0.6411 0.733 (0.537–1.002) 
0.0511 
Study 1104 
(phase II) 0.848 (0.589–1.223) 
0.3779 0.757 (0.499–1.150) 0.1923 
Study 2001 
(phase II) 1.294 (0.914–1.831) 
0.1465 0.924 (0.628–1.358) 0.6861 
 
CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; MIPI, mantle cell 
lymphoma international prognostic index. *Significant. 
 
  























































Fig 4. Forest plot of progression-free survival for pooled MCL analysis. 
 
 
CI, confidence interval; CVAD, central venous access device; ECOG, Eastern Cooperative Oncology 
Group; HR, hazard ratio; LDH, lactate dehydrogenase; MCL, mantle cell lymphoma; sMIPI, simplified 
MCL international prognostic index. 
  





Figure 5. Progression-free survival (PFS) and overall survival (OS) by baseline factors: (A) 
simplified MCL international prognostic index (sMIPI), (B) bulky disease, and (C) blastoid 
histology. 
 















(C) Blastoid histology yes vs. no 
 
